Table 1.
Baseline Patient Characteristics and Hospitalization Variables
| Hospitalization Characteristics | |||
|---|---|---|---|
| Total Subjects, n | 45 | ||
| Male Gender, n (%) | 26 (57.7) | ||
| Age in years, mean (SD) | 61.5 (13.9) | Age in years, median (IQR) | 60 (55–71) |
| Race, n (%) | Hispanic 25 (55.6) | White 9 (20) | Black 6 (13.33) |
| Other 3 (7.3) | Asian 2 (4.4) | ||
| Hospitalization Length of Stay (days) | |||
| LOS, mean (SD) | 22.3 (16.9) | LOS, median (IQR) | 18 (10–29) |
| Past Medical History | |||
| BMI, mean (SD) | 32.3 (7.2) | COPD, n (%) | 8 (17.7) |
| Obesity, n (%) | 26 (57.7) | Asthma, n (%) | 7 (15.5) |
| Hypertension, n (%) | 23 (51.1) | OSA, n (%) | 6 (13.3) |
| Diabetes, n (%) | 13 (28.8) | ILD, n (%) | 2 (4.4) |
| CKD, n (%) | 3 (6.6) | Pulmonary HTN, n (%) | 1 (2.2) |
| Cancer, n (%) | 2 (4.4) | Home O2, n (%) | 7 (15.5) |
| Heart Failure, n (%) | 7 (15.5) | Immunocompromise, n (%) | 4 (8.8) |
| Hospitalization Therapies | |||
| Shock, n (%) | 5 (11.1) | Positive BCx, n (%) | 3 (6.6) |
| Paralyzed, n (%) | 3 (6.6) | Positive RCx, n (%) | 3 (6.6) |
| VTE, n (%) | 9 (20) | Received Antibiotics, n (%) | 26 (57.7) |
| Received Anticoagulant, n (%) | 23 (51.1) | Received Dexamethasone, n (%) | 37 (82.2) |
| Received Tocilizumab, n (%) | 17 (37.7) | Received Plasma Trial, n (%) | 6 (13.3) |
| Received Remdisivir, n (%) | 36 (80) | ||
| Oxygen Requirements | |||
| HFNC, n (%) | 39 (86.6) | Placed NRB, n (%) | 34 (75.5) |
| NIV (BiPAP), n (%) | 7 (15.5) | Placed NRB only, n (%) | 3 (6.6) |
| IMV, n (%) | 7 (15.5) | ||
| Highest Fi02%, mean (SD) | 84.7 (15.1) | Highest FiO2%, median (IQR) | 90 (75–100) |
CKD Chronic kidney disease, COPD Chronic obstructive pulmonary disease, OSA Obstructive sleep apnea; ILD Interstitial lung disease; HTN Hypertension; VTE Venous thromboembolism, BCx Blood culture, RCx Respiratory culture, HFNC High-flow nasal canula, NIV Non-invasive ventilation, IMV Invasive mechanical ventilation, FiO2 Fraction of inspired oxygen, NRB Non-rebreather mask